|
Panel Lacks Consensus on Surrogate Endpoint for Aspirin Alternative
An FDA advisory panel could not reach a consensus on whether an effect on bypass graft failure could be used as an approvable trial endpoint for thromboxane receptor antagonists (TBAs) as an aspirin alternative for coronary artery bypass graft (CABG) patients.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives